Re-irradiation in head and neck cancers: an Indian tertiary cancer centre experience

Abstract

Re-irradiation of second primaries or recurrences of head and neck cancers with moderate radiation doses yields acceptable progression-free survival and morbidity rates.

Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer

“…Dornoff et al report 1 year overall survival rates for RT with cetuximab of 44.4% and of RT with cisplatin of 45.5% in a cohort of 66 re-irradiated patients with LRHNC (Dornoff et al, 2015). Other studies have yielded similar results with reports of median progression-free survival from re-irradiation of 15.0 months (Mallick et al, 2014) to 2 year overall survival rates of 43% (Riaz et al, 2014). Developments in modern radiation therapy such as stereotactic body radiation therapy (SBRT) delivered with concomitant cetuximab have yielded one year overall survival rates of 47.5% (Lartigau et al, 2013).…”

Malignant Peripheral Nerve Sheath Tumor of the Infraorbital Nerve

“…Keeping in mind his high cardiovascular risk, this surgical plan made it possible to perform the oncological resection, removal, and reconstruction all-in-one short operating period. Adjuvant treatments such as chemotherapy (doxorubicin) and radiotherapy are controversial 123181920. Our patient received postoperative chemotherapy without neither evidence of relapse in the area nor systemic illness during a period of 1 year (clinical and CT scan follow-up).…”

“…Adjuvant treatments such as chemotherapy (doxorubicin) and radiotherapy are controversial. [1][2][3][18][19][20] Our patient received postoperative chemotherapy without neither evidence of relapse in the area nor systemic illness during a period of 1 year (clinical and CT scan follow-up). At the end of said time frame, he developed bilateral pulmonary metastases, the complications of which lead to his death 6 months later.…”

“…Peripheral nerve sheath malignant tumors, also known as fusiform cells/Schwann cell malignant tumors, neurofibrosarcoma, or neurogenic sarcoma, represent 10% of soft tissue sarcomas, and only 8 to 16% of them are located in head and neck 12…”

“…Peripheral nerve sheath malignant tumors, also known as fusiform cells/Schwann cell malignant tumors, neurofibrosarcoma, or neurogenic sarcoma, represent 10% of soft tissue sarcomas, and only 8 to 16% of them are located in head and neck. 1,2 Malignant peripheral nerve cell tumor or malignant neurilemmoma is a form of cancer of the connective tissues surrounding nerves. It is classified as a sarcoma because of its origin and behavior.…”